Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$885.91 USD

885.91
315,151

+1.43 (0.16%)

Updated Oct 2, 2024 10:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly

by Zacks Equity Research

Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.

Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day.

Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound

by Zacks Equity Research

LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.

Kinjel Shah headshot

J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?

by Kinjel Shah

We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

by Zacks Equity Research

PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.

Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday

by Zacks Equity Research

VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.

Roche Obtains Approval For its Rare Blood Disorder Drug in the EU

by Zacks Equity Research

RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.

Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?

by Zacks Equity Research

MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.

Zacks.com featured highlights include Norwegian Cruise Line, Eli Lilly, The Progressive and Fortinet

by Zacks Equity Research

Norwegian Cruise Line, Eli Lilly, The Progressive and Fortinet have been highlighted in this Screen of The Week article.

The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace

by Zacks Equity Research

Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Eli Lilly, Chevron & Abbott

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Chevron Corporation (CVX) and Abbott Laboratories (ABT), as well as a micro-cap stocks Bridger Aerospace Group Holdings, Inc. (BAER).

Sanghamitra Saha headshot

Buy 4 Top-Ranked Stocks to Play Likely Earnings Beat

by Sanghamitra Saha

Top-ranked stocks Norwegian Cruise Line (NCLH), Eli Lilly (LLY), The Progressive (PGR) and Fortinet (FTNT) are likely to beat on earnings in their upcoming releases.

Here's Why You Should Consider Buying Akebia (AKBA) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.

J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa

by Zacks Equity Research

The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Sundeep Ganoria headshot

Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?

by Sundeep Ganoria

Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.

Kinjel Shah headshot

Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?

by Kinjel Shah

Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More

by Kinjel Shah

LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.

Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug

by Zacks Equity Research

Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.

Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk

by Zacks Equity Research

Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.

Company News for Aug 21, 2024

by Zacks Equity Research

Companies In The News Are: LLY, BA, AS, MDT.

Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly

by Zacks Equity Research

Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly have been highlighted in this Investment Ideas article.

Andrew Rocco headshot

Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed

by Andrew Rocco

Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.

Kinjel Shah headshot

How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?

by Kinjel Shah

After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE